Calidi Biotherapeutics (CLDI) Insider Trading & Ownership $1.54 -0.04 (-2.53%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.58 +0.03 (+2.27%) As of 09/19/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Calidi Biotherapeutics (NYSE:CLDI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.70%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$455KNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$16.19K Get CLDI Insider Trade Alerts Want to know when executives and insiders are buying or selling Calidi Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDI Insider Buying and Selling by Quarter Calidi Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/21/2025Andrew C JacksonCFOBuy2,500$2.00$5,000.00 8/21/2025Eric E PomaCEOBuy25,000$2.00$50,000.00 8/21/2025James A SchoeneckDirectorBuy75,000$2.00$150,000.00 8/21/2025Scott LeftwichDirectorBuy125,000$2.00$250,000.00 12/17/2024Allan CamaisaCEOSell833$19.44$16,193.52 (Data available from 1/1/2013 forward) CLDI Insider Trading Activity - Frequently Asked Questions Who is on Calidi Biotherapeutics' Insider Roster? The list of insiders at Calidi Biotherapeutics includes Allan Camaisa, Andrew C Jackson, Eric E Poma, James A Schoeneck, and Scott Leftwich. Learn more on insiders at CLDI. What percentage of Calidi Biotherapeutics stock is owned by insiders? 6.70% of Calidi Biotherapeutics stock is owned by insiders. Learn more on CLDI's insider holdings. Which Calidi Biotherapeutics insiders have been buying company stock? The following insiders have purchased CLDI shares in the last 24 months: Andrew C Jackson ($5,000.00), Eric E Poma ($50,000.00), James A Schoeneck ($150,000.00), and Scott Leftwich ($250,000.00). How much insider buying is happening at Calidi Biotherapeutics? Insiders have purchased a total of 227,500 CLDI shares in the last 24 months for a total of $455,000.00 bought. Which Calidi Biotherapeutics insiders have been selling company stock? The following insider sold CLDI shares in the last 24 months: Allan Camaisa ($16,193.52). How much insider selling is happening at Calidi Biotherapeutics? Insiders have sold a total of 833 Calidi Biotherapeutics shares in the last 24 months for a total of $16,193.52 sold. Calidi Biotherapeutics Key ExecutivesMr. Allan J. Camaisa (Age 64)CEO & Chairman of the Board Compensation: $306.18kMs. Wendy Pizarro Campbell Esq. (Age 53)Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary Compensation: $295.4kDr. Boris Minev M.D. (Age 61)Ph.D., President of Medical & Scientific Affairs and Interim Chief Medical Officer Compensation: $400.1kMr. Andrew C. Jackson (Age 55)Chief Financial Officer 1 recent tradesDr. Amish Patel Ph.D. (Age 47)Senior Vice President of Technical Operations Mr. Stephen Thesing (Age 58)Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies Lixte Biotechnology Insider Buying Promis Neurosciences Insider Buying Q32 Bio Insider Buying Sonnet BioTherapeutics Insider Buying Synergy CHC Insider Buying Aytu BioPharma Insider Buying Cingulate Insider Buying Finch Therapeutics Group Insider Buying Lexaria Bioscience Insider Buying Hoth Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity?Loop Industries Insiders Buy Stock, Signal Confidence in Outlook This page (NYSE:CLDI) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
